New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia ...
New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia by identifying the blood cancer's reliance on a specific signaling pathway ...
Dealbreaker on MSN
Takeda R&D exec explains how $1.2B deal could become one of the biggest bargains in drug history
Bispecific antibodies are one of the hottest areas for drug research and dealmaking, and several of them were discussed this ...
Detailed price information for Medicenna Therapeutics Corp (MDNAF) from The Globe and Mail including charting and trades.
GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE(R) natural killer (NK ...
ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...
GT Biopharma, Inc. (the "Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative ...
5d
Medicenna Therapeutics Corp.: Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook
ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, ...
The NEO-CYT study, sponsored by Fondazione Melanoma Onlus, will be evaluating MDNA11 in front-line therapy for resectable ...
QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback